Teva Tries its Luck with Risky NGF Inhibitor Class by Partnering with Regeneron

By Jawala Prasad

Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)

Published: 13 Oct-2016

DOI: 10.3833/pdr.v2016.i10.2201     ISSN: 1756-7874

Section: Licensing



Teva Pharmaceutical Industries has entered a development field abandoned by a number of big pharma companies by joining forces with Regeneron Pharmaceuticals to develop fasinumab (REGN475), an anti-NGF (nerve growth factor) antibody that is in Phase III development for osteoarthritis pain and Phase II for chronic low back pain...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details